Daiichi Sankyo's anti-clotting drug Savaysa gets FDA approval

January 9, 2015 10:02 AM

16 0

Japan-based Daiichi Sankyo has received approval from the US food and Drug Administration (FDA) for its anti-clotting drug, Savaysa (edoxaban tablets).

Savaysa is an oral, once-daily selective factor Xa-inhibitor developed to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF).

Read more

To category page